Atea Pharmaceuticals, Inc. (AVIR) Stock

About Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals, Inc. is led by CEO Jean-Pierre Sommadossi, employs 56 people, headquartered in US, publicly traded since 2020.

Atea Pharmaceuticals, Inc. (AVIR) stock trades at $4.04 with a market capitalization of $324.03M. The stock is valued at a negative price-to-earnings (P/E) ratio of -2.47, reflecting a net loss over the last twelve months, price-to-book of 2.01, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $2.84 and $6.45, and currently trades 37.4% below its 52-week high.

On profitability, Atea Pharmaceuticals, Inc. generates a return on equity (ROE) of -64.25% (negative, reflecting a net loss), return on capital employed of -89.93%.

Atea Pharmaceuticals, Inc. by the numbers, 2018–2025

Between 2018 and 2025 Atea Pharmaceuticals, Inc. reported revenue of $0 rising to $0. Compounded, revenue has grown —% a year over five years, —% over three, —% over the last twelve months. Net profit fell to $-158.0M.

On a trailing twelve-month basis to Jun '26, revenue is $0 and net profit $-165.0M.

Borrowings stand at $1.0M, cash from operations was $-132.0M in the latest year, positive in 1 of the last 8.

Return on equity has averaged -24.3% over five years, and was -57.5% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Atea Pharmaceuticals, Inc. (AVIR) — frequently asked questions